vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and RXO, Inc. (RXO). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.5B, roughly 1.9× RXO, Inc.). RXO, Inc. runs the higher net margin — -3.1% vs -3.7%, a 0.6% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -11.9%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $-9.0M). Over the past eight quarters, RXO, Inc.'s revenue compounded faster (26.8% CAGR vs 14.0%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
RXO, Inc. is a leading transportation and logistics solutions provider headquartered in the United States. Its core service portfolio includes freight brokerage, last-mile delivery for heavy and bulky goods, managed transportation services, and end-to-end supply chain optimization support, primarily catering to clients across the North American manufacturing, retail, and e-commerce segments.
BHC vs RXO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.5B |
| Net Profit | $-103.0M | $-46.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | -2.9% |
| Net Margin | -3.7% | -3.1% |
| Revenue YoY | 9.3% | -11.9% |
| Net Profit YoY | -205.1% | -84.0% |
| EPS (diluted) | $-0.30 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.5B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.3B | $1.4B | ||
| Q4 24 | $2.6B | $1.7B | ||
| Q3 24 | $2.5B | $1.0B | ||
| Q2 24 | $2.4B | $930.0M | ||
| Q1 24 | $2.2B | $913.0M |
| Q4 25 | $-103.0M | $-46.0M | ||
| Q3 25 | $179.0M | $-14.0M | ||
| Q2 25 | $148.0M | $-9.0M | ||
| Q1 25 | $-58.0M | $-31.0M | ||
| Q4 24 | $98.0M | $-25.0M | ||
| Q3 24 | $-85.0M | $-243.0M | ||
| Q2 24 | $10.0M | $-7.0M | ||
| Q1 24 | $-64.0M | $-15.0M |
| Q4 25 | 17.0% | -2.9% | ||
| Q3 25 | 23.1% | -0.5% | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 12.2% | -2.1% | ||
| Q4 24 | 21.8% | -1.4% | ||
| Q3 24 | 12.7% | -1.9% | ||
| Q2 24 | 16.2% | — | ||
| Q1 24 | 13.1% | -1.3% |
| Q4 25 | -3.7% | -3.1% | ||
| Q3 25 | 6.7% | -1.0% | ||
| Q2 25 | 5.8% | -0.6% | ||
| Q1 25 | -2.6% | -2.2% | ||
| Q4 24 | 3.8% | -1.5% | ||
| Q3 24 | -3.4% | -23.4% | ||
| Q2 24 | 0.4% | -0.8% | ||
| Q1 24 | -3.0% | -1.6% |
| Q4 25 | $-0.30 | $-0.28 | ||
| Q3 25 | $0.48 | $-0.08 | ||
| Q2 25 | $0.40 | $-0.05 | ||
| Q1 25 | $-0.16 | $-0.18 | ||
| Q4 24 | $0.24 | $-0.17 | ||
| Q3 24 | $-0.23 | $-1.81 | ||
| Q2 24 | $0.03 | $-0.06 | ||
| Q1 24 | $-0.17 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $17.0M |
| Total DebtLower is stronger | $20.8B | $387.0M |
| Stockholders' EquityBook value | $-554.0M | $1.5B |
| Total Assets | $26.4B | $3.3B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $17.0M | ||
| Q3 25 | $1.3B | $25.0M | ||
| Q2 25 | $1.7B | $18.0M | ||
| Q1 25 | $1.1B | $16.0M | ||
| Q4 24 | $1.2B | $35.0M | ||
| Q3 24 | $719.0M | $55.0M | ||
| Q2 24 | $595.0M | $7.0M | ||
| Q1 24 | $733.0M | $7.0M |
| Q4 25 | $20.8B | $387.0M | ||
| Q3 25 | $21.0B | $387.0M | ||
| Q2 25 | $21.7B | $387.0M | ||
| Q1 25 | $21.5B | $387.0M | ||
| Q4 24 | $21.6B | $351.0M | ||
| Q3 24 | $21.5B | $352.0M | ||
| Q2 24 | $21.7B | $370.0M | ||
| Q1 24 | $22.1B | $351.0M |
| Q4 25 | $-554.0M | $1.5B | ||
| Q3 25 | $-565.0M | $1.6B | ||
| Q2 25 | $-764.0M | $1.6B | ||
| Q1 25 | $-1.2B | $1.6B | ||
| Q4 24 | $-1.3B | $1.6B | ||
| Q3 24 | $-1.2B | $1.7B | ||
| Q2 24 | $-1.2B | $579.0M | ||
| Q1 24 | $-1.1B | $582.0M |
| Q4 25 | $26.4B | $3.3B | ||
| Q3 25 | $26.8B | $3.2B | ||
| Q2 25 | $27.3B | $3.2B | ||
| Q1 25 | $26.4B | $3.3B | ||
| Q4 24 | $26.5B | $3.4B | ||
| Q3 24 | $26.5B | $3.4B | ||
| Q2 24 | $26.5B | $1.8B | ||
| Q1 24 | $26.9B | $1.8B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $7.0M |
| Free Cash FlowOCF − Capex | $403.0M | $-9.0M |
| FCF MarginFCF / Revenue | 14.4% | -0.6% |
| Capex IntensityCapex / Revenue | 3.3% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $-8.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $7.0M | ||
| Q3 25 | $405.0M | $23.0M | ||
| Q2 25 | $289.0M | $23.0M | ||
| Q1 25 | $211.0M | $-2.0M | ||
| Q4 24 | $601.0M | $-7.0M | ||
| Q3 24 | $405.0M | $-7.0M | ||
| Q2 24 | $380.0M | $-5.0M | ||
| Q1 24 | $211.0M | $7.0M |
| Q4 25 | $403.0M | $-9.0M | ||
| Q3 25 | $314.0M | $9.0M | ||
| Q2 25 | $190.0M | $9.0M | ||
| Q1 25 | $96.0M | $-17.0M | ||
| Q4 24 | $495.0M | $-19.0M | ||
| Q3 24 | $334.0M | $-18.0M | ||
| Q2 24 | $302.0M | $-16.0M | ||
| Q1 24 | $129.0M | $-4.0M |
| Q4 25 | 14.4% | -0.6% | ||
| Q3 25 | 11.7% | 0.6% | ||
| Q2 25 | 7.5% | 0.6% | ||
| Q1 25 | 4.2% | -1.2% | ||
| Q4 24 | 19.3% | -1.1% | ||
| Q3 24 | 13.3% | -1.7% | ||
| Q2 24 | 12.6% | -1.7% | ||
| Q1 24 | 6.0% | -0.4% |
| Q4 25 | 3.3% | 1.1% | ||
| Q3 25 | 3.4% | 1.0% | ||
| Q2 25 | 3.9% | 1.0% | ||
| Q1 25 | 5.1% | 1.0% | ||
| Q4 24 | 4.1% | 0.7% | ||
| Q3 24 | 2.8% | 1.1% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 3.8% | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | 2.26× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
